Janux Therapeutics, Inc.

About Janux Therapeutics, Inc.

Janux Therapeutics is dedicated to developing precision-engineered immunotherapies to transform the lives of patients, focusing on enabling them to prioritize what matters most. Their mission centers on creating innovative treatments for cancer and autoimmune diseases through selective modulation of T cells.

Products & Services

PSMA-TRACTr (JANX007):A tumor-activated T cell engager targeting prostate cancer, currently in clinical trials.

EGFR-TRACTr (JANX008):A T cell engager focused on EGFR-related cancer targets.

TROP2-TRACTr:A T cell engager targeting TROP2 for cancer treatment.

PSMA-TRACIr:A platform for immune regulation related to PSMA targets.

CD19-ARM:A program focused on CD19 for potential cancer or autoimmune applications.

TRACTr and TRACIr Platforms:Innovative platforms for designing bispecific molecules to stimulate the immune system safely.

ARM Platform:A platform for developing therapies with immune modulation capabilities.

Specialties

Immunotherapies T Cell Engagers Bispecific Molecules Cancer Treatment Autoimmune Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 402500000 MR: - FA: $402.5 million FAN: 402500000	D: 2024-12-06 FD: 2024-12-06	9 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 350000000 MR: - FA: $350.0 million FAN: 350000000	D: 2024-12-05 FD: 2024-12-05	9 investors
3	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: $300.0 million FAN: 300000000	D: 2024-12-03 FD: 2024-12-03	9 investors
4	RT: Public Offering T: - FT: Public Offering	A: 296500000 MR: - FA: 296.5 million FAN: 296500000	D: 2024-02-29 FD: 2024-02-29	6 investors
5	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 175000000 MR: - FA: $175.0 million FAN: 175000000	D: 2024-02-27 FD: 2024-02-27	4 investors
6	RT: Underwritten Offering of Common Stock and Pre-Funded Warrants T: - FT: Underwritten Offering of Common Stock and Pre-Funded Warrants	A: 60000000 MR: - FA: $60 million FAN: 60000000	D: 2023-07-17 FD: 2023-07-17	1 investors

Underwritten Public Offering Latest

2024-12-06

$402.5M

9 investors (Pro only)

Underwritten Public Offering 2024-12-05

$350.0M

Public Offering 2024-12-03

$300.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Campbell

Founder, President & Chief Executive Officer

T

Tommy DiRaimondo

Chief Scientific Officer

J

Janeen Doyle

Chief Corporate and Business Development Officer

Z

Zachariah McIver

Chief Medical Officer

A

Andy Meyer

Chief Business Officer

C

Charles Winter

Chief Technical Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News